Vascular News’ top 10 most popular stories of June 2022

4046

popularCoverage of this year’s Leipzig Interventional Course (LINC; 6–9 June, Leipzig, Germany) and Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 15–18 June, Boston, USA) proved popular amongst Vascular News readers in June, as did some new research on carotid interventions. 

1. Research indicates low stroke risk and benefit of medication alone in asymptomatic carotid stenosis

The risk of having a future stroke caused by asymptomatic carotid stenosis is “so low” that most patients with this condition could potentially be treated with the newest medications and may not require surgery. That is according to new research from Kaiser Permanente.

2. New data support covered stent use in complex aortoiliac occlusive disease treatment

One-year outcomes from the BELSTREAM trial add to a growing pool of data that covered stents are safe and effective in the treatment of complex aortoiliac occlusive disease (AIOD).

3. F/BEVAR has high technical success and low mortality in chronic post-dissection TAAA

Fenestrated/branched endovascular aneurysm repair (F/BEVAR) is associated with high technical success and low mortality in patients with chronic post-dissection thoracoabdominal aortic aneurysm (PD-TAAA). This conclusion was presented by Mohamed A Abdelhalim (St Thomas’ Hospital, London, UK), who detailed a multicentre, transatlantic experience with F/BEVAR for chronic PD-TAAAs during this year’s Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2022; 15–18 June, Boston, USA).

4. Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

Based on over four years of experience in a single centre, Robert Shahverdyan (Asklepios Klinik Barmbek, Hamburg, Germany) claims that endovascular arteriovenous fistula (endoAVF) creation “keeps future options open,” but is not a replacement for surgical fistula creation.

5. Revascularisation strategy for BTK intervention should hinge on diagnostic modality, LINC audience hears

New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg (Arnsberg Vascular Center, Arnsberg, Germany), who presented one-year outcomes from the PRESTIGE pilot study at the Leipzig Interventional Course (LINC) 2022 (6–9 June, Leipzig, Germany).

6. Carotid stenting demonstrates comparable short- and long-term results to endarterectomy

Pooled patient-level data from more than 2,500 asymptomatic, non-octogenarian subjects have shown that carotid artery stenting (CAS) achieved comparable short- and long-term results to carotid endarterectomy (CEA). The findings of this analysis have been published by Jon Matsumura (University of Wisconsin, Madison, USA) and colleagues in the Journal of Vascular Surgery.

7. Cydar Medical announces strategic collaboration with Brainlab

Cydar Medical has announced a collaboration with Brainlab, enabling its Cydar EV Maps augmented intelligence software to integrate with Brainlab’s Buzz digital information hub.

8. Artio Medical closes US$28 million in additional Series A financing

Artio Medical recently announced the closing of US$28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised by the company to date to US$74 million.

9. VasQ external support comparative US study results presented at VASA 2022

Laminate Medical Technologies press release reports that the US VasQ external support comparative study results were presented this month for the first time globally at the Vascular Access Society of the Americas (VASA) 2022 Vascular Access for Hemodialysis Symposium (9–11 June, Charleston, USA).

10. Cordis announces successful first-in-human use of the Radianz radial peripheral system

Cordis recently announced the first-in-human use of the Radianz radial peripheral system by Jihad Mustapha at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, USA.


LEAVE A REPLY

Please enter your comment!
Please enter your name here